You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 22, 2024

Blueprint Medicines Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?

BLUEPRINT MEDICINES has two approved drugs.

There are seven US patents protecting BLUEPRINT MEDICINES drugs.

There are ninety-seven patent family members on BLUEPRINT MEDICINES drugs in forty countries and sixteen supplementary protection certificates in fourteen countries.

Summary for Blueprint Medicines
International Patents:97
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Blueprint Medicines

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-001 Jan 9, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-005 Jun 16, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-003 Jan 9, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-004 Jun 16, 2021 RX Yes No 9,200,002 ⤷  Try a Trial Y Y ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-005 Jun 16, 2021 RX Yes No 9,200,002 ⤷  Try a Trial Y Y ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-002 Jan 9, 2020 RX Yes No 9,944,651 ⤷  Try a Trial Y Y ⤷  Try a Trial
Blueprint Medicines GAVRETO pralsetinib CAPSULE;ORAL 213721-001 Sep 4, 2020 RX Yes Yes 10,030,005 ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Blueprint Medicines Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3057969 132021000000035 Italy ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB E SUOI SALI FARMACEUTICAMENTE ACCETTABILI(AYVAKYT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1473, 20200925
3057969 CR 2021 00008 Denmark ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925
3057969 301094 Netherlands ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/20/1473 20200925
3057969 CA 2021 00008 Denmark ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925
3057969 21C1013 France ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925
3057969 PA2021003,C3057969 Lithuania ⤷  Try a Trial PRODUCT NAME: AVAPRITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924
3057969 C20210005 00320 Estonia ⤷  Try a Trial PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.